Journal: Gastric Cancer

Article Title: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

doi: 10.1007/s10120-014-0402-y

Figure Lengend Snippet: HER2 testing results from the screening phase of the study, according to immunohistochemistry and fluorescence in situ hybridization

Article Snippet: HER2 screening in the ToGA study was performed in a central testing laboratory (Targos Molecular Pathology GmbH); it is anticipated that HER2-positivity rates may vary when HER2 testing data are reported from regional centers, further highlighting the need for standardized HER2 testing and scoring and the use of accurate and validated assays [ ].

Techniques: Immunohistochemistry, Fluorescence, In Situ

Journal: Gastric Cancer

Article Title: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

doi: 10.1007/s10120-014-0402-y

Figure Lengend Snippet: HER2 testing results in patients potentially eligible for enrollment into ToGA, according to immunohistochemistry and fluorescence in situ hybridization

Article Snippet: HER2 screening in the ToGA study was performed in a central testing laboratory (Targos Molecular Pathology GmbH); it is anticipated that HER2-positivity rates may vary when HER2 testing data are reported from regional centers, further highlighting the need for standardized HER2 testing and scoring and the use of accurate and validated assays [ ].

Techniques: Immunohistochemistry, Fluorescence, In Situ

Journal: Gastric Cancer

Article Title: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

doi: 10.1007/s10120-014-0402-y

Figure Lengend Snippet: Proportion of tumors that tested positive for HER2 based on data from all patients screened and from patients successfully screened by immunohistochemistry or fluorescence in situ hybridization, according to patient demographics and tumor characteristics

Article Snippet: HER2 screening in the ToGA study was performed in a central testing laboratory (Targos Molecular Pathology GmbH); it is anticipated that HER2-positivity rates may vary when HER2 testing data are reported from regional centers, further highlighting the need for standardized HER2 testing and scoring and the use of accurate and validated assays [ ].

Techniques: Immunohistochemistry, Fluorescence, In Situ Hybridization

Journal: Gastric Cancer

Article Title: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

doi: 10.1007/s10120-014-0402-y

Figure Lengend Snippet: Proportion of patients with tumor HER2 staining variability (≤30 % stained cells) by IHC category

Article Snippet: HER2 screening in the ToGA study was performed in a central testing laboratory (Targos Molecular Pathology GmbH); it is anticipated that HER2-positivity rates may vary when HER2 testing data are reported from regional centers, further highlighting the need for standardized HER2 testing and scoring and the use of accurate and validated assays [ ].

Techniques: Staining

Journal: Gastric Cancer

Article Title: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

doi: 10.1007/s10120-014-0402-y

Figure Lengend Snippet: Efficacy of trastuzumab plus chemotherapy vs. chemotherapy alone according to HER2 expression status (screened by immunohistochemistry or fluorescence in situ hybridization)

Article Snippet: HER2 screening in the ToGA study was performed in a central testing laboratory (Targos Molecular Pathology GmbH); it is anticipated that HER2-positivity rates may vary when HER2 testing data are reported from regional centers, further highlighting the need for standardized HER2 testing and scoring and the use of accurate and validated assays [ ].

Techniques: Expressing, Immunohistochemistry, Fluorescence, In Situ Hybridization

Journal: iScience

Article Title: Reinvestigating the clinical relevance of the m 6 A writer METTL3 in urothelial carcinoma of the bladder

doi: 10.1016/j.isci.2023.107300

Figure Lengend Snippet:

Article Snippet: XTRAKT FFPE kit , Stratifyer , Cat#XTK2.0-96.

Techniques: Western Blot, Expressing, Real-time Polymerase Chain Reaction, Recombinant, Cell Viability Assay, Caspase-Glo Assay, Purification, CRISPR, Software

Journal: JNCI Cancer Spectrum

Article Title: MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

doi: 10.1093/jncics/pkab054

Figure Lengend Snippet: Patient clinical characteristics in all B-34 patients according to treatment arm and MAF amplification status

Article Snippet: MAF gene amplification testing by a central laboratory (Targos Molecular Pathology, Kassel, Germany) was blinded and followed prespecified sample handling and standard operating methodology.

Techniques: Amplification, Adjuvant